Capricor/$CAPR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Capricor

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Ticker

$CAPR
Primary listing

Industry

Biotechnology

Employees

160

ISIN

US14070B3096

Capricor Metrics

BasicAdvanced
$465M
-
-$1.42
0.86
-

What the Analysts think about Capricor

Analyst ratings (Buy, Hold, Sell) for Capricor stock.

Bulls say / Bears say

Capricor Therapeutics' lead candidate, deramiocel, has received FDA Priority Review for its Biologics License Application, with a target action date of August 31, 2025, indicating potential for expedited approval and market entry. (Investing.com)
Analysts are optimistic about Capricor's prospects, with HC Wainwright reiterating a 'Buy' rating and a $77.00 price target, reflecting confidence in the company's growth potential. (ETF Daily News)
Capricor has secured a $10 million milestone payment from Nippon Shinyaku and maintains a robust cash balance, positioning the company well for continued operations and expansion into 2027. (TipRanks)
Despite positive developments, Capricor reported a 7.9% year-over-year decline in revenue for Q4 2024, which may raise concerns about the company's current financial performance. (TipRanks)
The company's stock has exhibited high volatility, with a beta of 4.10, indicating that it is significantly more volatile than the broader market, which could deter risk-averse investors. (ETF Daily News)
Capricor's reliance on a single lead product, deramiocel, for future growth presents a concentration risk; any setbacks in its approval or commercialization could adversely affect the company's financial outlook. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

Capricor Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Capricor Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CAPR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs